Center for Global Development’s “Global Health Policy Blog”: The 5000% Price Increase and the Economic Case for Pharma Price Regulation
In light of a recent move by Turing Pharmaceuticals CEO Martin Shkreli to increase the price of the toxoplasmosis drug Daraprim by more than 5,000% overnight, CGD Senior Fellow Mead Over and Senior Policy Analyst Rachel Silverman discuss the global health implications of potential pharmaceutical pricing regulations. “…Just as utility companies best serve the public interest under government regulation for their local markets, multinational pharmaceutical companies would best serve global health under global regulation that supervises their international pricing as well as their research expenditures…” (9/23).